HomeFUNDING
FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
Cytomos Secures £5M | To Scale Up Production of Cell-analysis Technology
New investment will allow Cytomos to drive sales of its first commercial product, Celledonia™, built on its cell-analysis technology platform AuraCyt, which is already generating significant market traction.
TactoTek Secures $60 Million in Funding Led by Virala Group
With this funding, TactoTek will accelerate the adoption of IMSE globally by expanding customer-facing operations and streamlining IMSE solution design by augmenting our software-based delivery system with AI elements and plug-ins for CAD and simulation packages
Predictive Heart Monitoring Startup, GPx, Secures NEC X Investment
“GPx’s innovative approach to heart monitoring and chronic disease management is a perfect fit for the NEC Group’s vision of leveraging advanced technology to improve quality of life,” said Shintaro Matsumoto, President and CEO of NEC X. “By joining forces with GPx, we aim to enhance their predictive algorithms and capabilities. Together, we can transform the healthcare industry.”
Bright Uro Announces Oversubscribed $32M Series A Funding Round
Derek Herrera, founder and CEO of Bright Uro. "With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues."
Nuclera Closes $75 Million USD Financing
The funding will accelerate the commercialization of the Nuclera eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally
Biocomposites Invests in InfectoTest GmbH | Developers of a Bacterial-specific Point-of-care Test for Periprosthetic Joint infection
Michael Harris, Chief Executive Officer of Biocomposites, said: “Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery.
Syncona: Resolution Therapeutics Raises £63.5 Million in Series B Financing | Appoints New Chair
Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO.
Celaid Therapeutics Inc. Secures up to $19M Grant from the Japanese Agency for Medical Research and Development
Celaid Therapeutics secures up to approx. $19M non-dilutive grant funding from Japanese government. The grant funding will support the development of Celaid's hematopoietic stem cell product for pediatric non-malignant diseases.
Nordic Biotech Company Pila Pharma Raises Capital for New International Obesity Study
According to According to Pila Pharma, the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment., the capital raised will support the study with the objective to assess the molecule’s safety in increased dosages, as well as to expand on the number of study participants to determine, though empirical statistical calculations, whether the molecule has potential as part of a new tablet-based obesity treatment.
